Systemic Lupus Erythematosus
Conditions
Keywords
SLE
Brief summary
This is a Phase I, randomized, placebo-controlled, double-blind, dose-escalation study of single and repeat doses of rhuMAb IFNalpha, administered through the SC or IV route, in adults with Systemic Lupus Erythematosus.
Interventions
DRUGrhuMAb IFNalpha
Intravenous repeating dose
Sponsors
Genentech, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* For patients with reproductive potential (males and females), use of a reliable means of contraception (e.g., hormonal contraceptive, patch, vaginal ring, intrauterine device, physical barrier) throughout their participation in the study * Diagnosis of SLE according to current American College of Rheumatology (ACR) criteria * Disease duration of ≥ 1 year (after first diagnosis by a physician) * Current immunity to measles, mumps, rubella, and varicella, as evidenced by positive IgG titers at the time of screening * Current vaccination against influenza unless contraindicated in the investigator's judgment * Normal Pap smear within the applicable time interval recommended by current American Cancer Society guidelines
Exclusion criteria
* Presence of active lupus nephritis * Presence of active central nervous system (CNS) disease requiring treatment with high-dose corticosteroids or immunosuppressive agents * Presence of active vasculitis requiring treatment * History of arterial or venous thromboses within 12 months of screening * Moderate to severe anemia, thrombocytopenia, or neutropenia * Any manifestation likely to require, in the investigator's judgment, treatment with high-dose corticosteroids or the addition of an immunosuppressive regimen during the course of the trial * Pregnancy or lactation * Lack of peripheral venous access * History of alcohol or substance abuse within 6 months of screening * History of severe allergic or anaphylactic reactions to antibodies or fusion proteins * Evidence of significant uncontrolled concomitant diseases * Significant laboratory or electrocardiogram (ECG) abnormalities * Evidence of any clinically significant abnormality on a chest X-ray * Severly impaired renal function * Impaired hepatic function * Poorly controlled diabetes * Conditions other than SLE that could require treatment with corticosteroids * History of malignancy except completely excised basal cell carcinoma * Congenital immune deficiency * Positive tests for antibodies to HIV, hepatitis B (HBS antigen, anti-HBC) or C * Positive IgM antibody titers in the presence of negative IgG titers to Epstein-Barr virus (EBV) or cytomegalovirus (CMV) * Frequent recurrence of herpes lesions * Episode of shingles within one year of screening * Positive screening test for latent mycobacterium tuberculosis infection * History of severe systemic bacterial, fungal, viral, or parasitic infections within the year prior to screening * Any current or recent signs or symptoms of infection * Received antibiotics orally (PO) during the 30 days prior to screening or IV antibiotics during the 60 days prior to screening * Received a live vaccine within the 30 days prior to screening * Has been hospitalized within the 30 days prior to screening * Received \> 20 mg/day prednisone for \> 3 days during the 30 days prior to screening * Received azathioprine, methotrexate, mycophenolate mofetil, cyclosporine, tacrolimus, sirolimus, pulse dose corticosteroids, intravenous immunoglobulin (IVIG), or transfusions within 6 months prior to screening * Received cyclophosphamide within 2 years prior to screening * Received a monoclonal antibody during the 12 months prior to screening * Previously received an investigational treatment directed against interferon alpha * Received B-cell depleting therapy (e.g., anti-CD20, anti-CD22) * Received investigational treatment during the 30 days prior to screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence, nature, and severity of adverse events | Length of study |
| The incidence and nature of laboratory abnormalities | Length of study |
Secondary
| Measure | Time frame |
|---|---|
| The PK profile of rhuMAb IFNalpha | Length of study |
| The incidence of antibodies directed against rhuMAb IFNalpha | Length of study |
Outcome results
None listed